In the Claims:

Please cancel claims 31 and 51 without prejudice or disclaimer and please amend claim 28, 32 and 48. The following listing of the claims will replace all prior versions, and listings, of claims in the application:

1. - 27. (Canceled)

28. (Previously Presented) A method for treating a solid cancer or haematological malignancy comprising a membrane androgen receptor (mAR), the method comprising administering to a patient in need thereof a composition comprising: (a) one or more androgen steroids excluding cytostaticum, wherein the androgen steroid is covalently attached to a mammalian protein excluding an antibody; and (b) a cytoskeleton-acting drug.

29. (Previously Presented) The method of claim 28, wherein the solid cancer is one of prostate adenocarcinoma (hormone sensitive or resistant) and metastases thereof, breast cancer and metastases thereof, pheochromocytomas and metastases thereof, bone tumor and metastases thereof and brain tumor (neuroblastomas).

30. (Previously Presented) The method of claim 28, wherein the haematological malignancies are acute and chronic myeloid leukemia, acute and chronic lymphoid leukaemia and lymphomas (B and T).

31. (Cancelled)

32. (Currently Amended) The method of claim 28 ~~31~~, wherein the androgen steroid is testosterone.

33. (Previously Presented) The method of claim 28, wherein the mammalian protein is a recombinant or isolated natural serum albumin.

34. (Previously Presented) The method of claim 28, wherein the composition is detectably-labeled.

35. (Previously Presented) The method of claim 32, wherein the testosterone is covalently attached to the mammalian protein through a carboxy-methyl ether linker.

36. (Previously Presented) The method of claim 35, wherein the linker is covalently attached to the testosterone at the 3' position of the steroidal ring.

37. (Previously Presented) The method of claim 28, wherein the cytoskeleton-acting drug is Taxol or Taxotere.

38. (Withdrawn) The method of claim 28, the composition further comprises an antiandrogen.

39. (Withdrawn) The method of claim 38, wherein the antiandrogen is present in about a 10-fold molar excess relative to the molar amount of the one more steroids.

40. (Withdrawn) The method of claim 28, wherein the administration of the composition is parenteral, percutaneous or intravenous.

41. (Previously Presented) The method of claim 28, wherein the composition is administered at least once daily.

42. (Withdrawn) The method of claim 28, wherein the method further comprises the step of administering an antiandrogen to the patient.

43. (Previously Presented) The method of claim 28, wherein the method further comprises the step of decreasing solid cancer mass in the patient.

44. (Previously Presented) A method for treating prostate cancer comprising administering to a patient in need thereof composition comprising Testosterone3-(O-carboxymethyl)oxime-human serum albumin and Taxol or Taxotere.

45. (Previously Presented) The method of claim 44, wherein the composition further comprises an antiandrogen.

46. (Previously Presented) The method of claim 44, wherein the method further comprises the step of administering an antiandrogen to the patient.

47. (Previously Presented) The method of claim 44, wherein the method further comprises the step of decreasing prostate cancer mass in the patient.

48. (Currently Amended) A method for treating a solid cancer or haematological malignancy comprising comprising a membrane androgen receptor (mAR), the method comprising administering to a patient in need thereof a composition comprising: (a) one or more androgen steroids excluding cytostaticum, wherein the androgen steroid is covalently attached to a mammalian protein excluding an antibody selected from the group consisting of a globular protein, a plasma protein, and albumin ~~and a binder~~; and (b) a cytoskeleton-acting drug.

49. (Previously Presented) The method of claim 48, wherein the solid cancer is one of prostate adenocarcinoma (hormone sensitive or resistant) and metastases thereof, breast cancer and metastases thereof, pheochromocytomas and metastases thereof, bone tumor and metastases thereof and brain tumor (neuroblastomas).

50. (Previously Presented) The method of claim 48, wherein the haematological malignancies are acute and chronic myeloid leukemia, acute and chronic lymphoid leukaemia and lymphomas (B and T).

51. (Cancelled).

52. (Currently Amended) The method of claim 48 ~~51~~, wherein the androgen steroid is testosterone.

53. (Previously Presented) The method of claim 48, wherein the mammalian protein is a recombinant or isolated natural serum albumin.

54. (Previously Presented) The method of claim 48, wherein the composition is detectably-labeled.

55. (Previously Presented) The method of claim 52, wherein the testosterone is covalently attached to the mammalian protein through a carboxy-methyl ether linker.

56. (Previously Presented) The method of claim 55, wherein the linker is covalently attached to the testosterone at the 3' position of the steroidal ring.

57. (Previously Presented) The method of claim 48, wherein the cytoskeleton-acting drug is Taxol or Taxotere.

58. (Previously Presented) The method of claim 48, wherein the composition is administered at least once daily.

59. (Previously Presented) The method of claim 48, wherein the method further comprises the step of decreasing solid cancer mass in the patient.